45 results about "Diffuse large cell lymphoma" patented technology

The present invention relates to methods of treating cancers, e.g., mesothelioma or lymphoma. More specifically, the present invention relates to methods of treating mesothelioma or diffuse large B-cell lymphoma (DLBCL), by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

The invention is directed to a method of prognosing in an individual a transformation from follicular lymphoma to diffuse large B-cell lymphoma (DLBCL) by measuring changes and / or lack of changes in certain groups of related clonotypes, referred to herein as “clans,” in successive clonotype profiles of the individual. A clan may arise from a single lymphocyte progenitor that gives rise to many related lymphocyte progeny, each possessing and / or expressing a slightly different immunoglobulin receptor due to somatic mutation(s), such as base substitutions, inversions, related rearrangements resulting in common V(D)J gene segment usage, or the like. A higher likelihood of transformation from follicular lymphoma to DLBCL is correlated with the persistence of clans in successive clonotype profiles whose clonotype membership fails to undergo diversification over time.

The present invention relates to methods of treating cancers, e.g., lymphoma. More specifically, the present invention relates to methods of treating diffuse large B-cell lymphoma (DLBCL), by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

Disclosed are non-human animal models, and preferably, rodent models, and more preferably, mouse models, of B-cell Non-Hodgkin's Lymphoma (NHL). In particular, the present invention provides animal models of B cell NHL including, B cell chronic lymphocytic leukemia / lymphoma (B-CLL), Burkitt's lymphoma (BL), Follicular-like lymphoma (FLL) and Diffuse large B-cell lymphoma (DLBCL), as well as various methods for producing these non-human animal models. These animal models, as well as cell lines produced from or derived from these models, are useful tools for a variety of methods, including, but not limited to, preclinical testing of drug candidates, and particularly drug candidates that are specific for human proteins, and any research, development, pharmaceutical, or clinical purpose, including but not limited to, the identification, development, and / or testing of drugs (therapeutics, prophylactics, etc.), targets, markers, and / or research tools for use in the diagnosis of, study of, or treatment of any Non-Hodgkin's Lymphoma, such as those described herein, or for any related condition.

The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of DLBCL. In particular, the instant disclosure provides a DLBCL classifier that has identified at least five distinct classes of DLBCL cancer, each of which possesses distinct pathogenic mechanisms and outcomes. The instant classifier identifies preferred therapeutic options (including combination therapies) for each such class of DLBCL cancer.

The invention discloses a molecular pathological classification method of diffuse large B-cell lymphomata, which use three quantum dot markers of different wavelengths as fluorescent probes to detect the expression of CD10, Bcl-6 and MUM1 proteins in a biological sample. The invention also discloses a kit for the molecular pathological classification of diffuse large B-cell lymphomata and an application thereof. The molecular pathological classification method of diffuse large B-cell lymphomata obviously improves the working efficiency, and can provide a rational regimen for patients with diffuse large B-cell lymphomata, thereby being beneficial to saving medical expenses.

The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients.

A method of treating diffuse large B-cell lymphoma comprising administering to a patient a pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound, said thienotriazolodiazepine compound being represented by Formula (I), wherein R1 is alkyl having a carbon number of 1-4, R2 is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, R3 is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; —NR5—(CH2)m—R6 wherein R5 is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R6 is phenyl or pyridyl optionally substituted by a halogen atom; or —NR7—CO—(CH2)n—R8 wherein R7 is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and R8 is phenyl or pyridyl optionally substituted by a halogen atom, and R4 is —(CH2)a—CO—NH—R9 wherein a is an integer of 1-4, and R9 is alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or —(CH2)b—COOR10 wherein b is an integer of 1-4, and R10 is alkyl having a carbon number of 1-4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof, wherein the patient has activated B-cell diffuse large B-cell lymphoma.

The invention belongs to the field of biological and medical examination, and relates to a detection method of a molecular tying marker of a diffuse large B-cell lymphoma, and a kit related to the detection method. The invention firstly provides the detection method of the molecular marker of the diffuse large B-cell lymphoma, which comprises the steps as follows: 1) a biomacromolecule combined with the specificity of the molecular marker is contacted with a biological sample taken from a diffuse large B-cell lymphoma patient; 2) the expression level of the molecular marker in the biological sample is determined; and 3) a judgment model is established according to a detection result of the molecular marker. The invention further provides the application of the method to molecular tying of the diffuse large B-cell lymphoma, and the corresponding kit. The method provided by the invention can be used for judging a molecular subtype of the diffuse large B-cell lymphoma, estimating the prognosis of the patient and providing a basis for early intervention treatment and the implementation of individualized treatment.

The invention provides a benzyloxy aromatic ring structure compound represented by a general formula (I), a stereoisomer, an enantiomer or a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition containing the same, and uses thereof. The compound shown in the general formula (I) can be used for preparing a small-molecule inhibitor of PD1 / PDL1 interaction, and can be used for preventing and / or treating diseases related to PD1 / PDL1 interaction, especially cancers, such as non-small cell lung cancer, small cell lung cancer, melanoma, head and neck cancer, kidney cancer, bladder cancer, local advanced or metastatic urothelial cancer, breast cancer, cervical cancer, metastatic Merkel cell cancer, prostate cancer, liver cancer, intestinal cancer, stomach cancer, multiple myeloma, mantle cell lymphoma, diffuse large B cell lymphoma, liver cancer, hodgkin lymphoma, chronic lymphocytic leukemia, squamous cell carcinoma and the like.

The present invention relates to a method for classifying a diffuse large B-cell lymphoma (DLBCL) of a subject into a GCB-DLBCL or into a ABC-DLBCL comprising the step of determining the expression level of 10 genes in a tumor tissue sample obtained from the subject by performing a Reverse Transcriptase Multiplex Ligation dependent Probe Amplification (RT-MLPA) assay wherein the 10 genes are NEK6, IRF4, IGHM, LMO2, FOXP1, TNFRSF9, BCL6, TNFRSF13B, CCND2 and MYBL1.

Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric / gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRPα D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody). Also provided are related kits pharmaceutical compositions.

Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and / or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.

Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric / gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRPα D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody). Also provided are related kits pharmaceutical compositions.

The invention discloses a nucleotide sequence which aims at the specificity T cell receptor of relative antigen of diffuse large b-cell lymphoma and the application, TCR V beta 13 sub-family in peripheral blood of DLBL patients is scanned and analyzed to take obvious monoclone through RT-PCR gens, a V-NDN-J area of specificity TCR sequence for sequencing PCR products namely a complementary-determining region 3 is a portion which combines with antigen specificity recognition, which expresses specificity TCR which is produced by the stimulation of TCR of clonal T cell for relative antigen of DLBL. The nucleotide sequence is a base and a key for adoptive cellular immunotherapy of DLBL molecular target through TCR transgenic technology. The nucleotide sequence of the specificity TCR is an important base for further developing specific cell immunization therapy which aims at lymphoma.

Provided are methods of determining cell of origin (COO) for diffuse large B Cell lymphoma (DLBCL) using DNA for the analysis. The methods include identification of DLBCL COO as activated B Cell (ABC) and germinal center B Cell (GCB).

The present invention relates generally to classification of biological samples, and more specifically to cell of original classification. In particular, some embodiments of the invention relate to diffuse large B cell lymphoma cell of origin classification using machine learning models. The machine learning models can be based on decision trees such as a random forest algorithm or a gradient boosted decision tree. Features for the models can be determined through analysis of variant data from plasma or blood samples from a plurality of subjects with the disease.

The invention provides application of chlorogenic acid in preparation of a medicine for treating central nervous system tumors, and belongs to the field of medicines. It is found for the first time that chlorogenic acid can effectively treat diffuse large B-cell lymphoma, a new and high-safety choice is provided for clinical treatment of central nervous system tumors, especially diffuse large B-cell lymphoma, and the chlorogenic acid has a good application prospect.

The invention discloses a diffuse large B-cell lymphoma prognosis model based on MYC / BCL2 double expression and an immune microenvironment, application and a prognosis method. Based on the MYC / BCL2 protein expression level and the immune microenvironment, the MYC / BCL2 protein expression level and the immune microenvironment synergistically play a unique role in prognosis of various DLBCL subtype patients, assist clinicians in judging clinical development and disease outcome of the patients, and realize precise layered treatment.

A method of predicting if a subject has an Activated B Cell-like (ABC) subtype or a non-ABC subtype of Diffuse Large B-Cell Lymphoma (DLBCL), comprising (a) obtaining a sample from the subject; (b) measuring the expression levels of CD10, MUM1, FOXP1, and optionally Bcl-6; (c) determining a composite score based on the expression levels of CD10, MUM1, and FOXP1, and optionally Bcl-6; and (d) predicting if the subject has an ABC subtype or a non-ABC subtype of DLBCL based on the composite score.

The invention relates to novel combination therapies involving anti-CD19 antibodies for the treatment of cancer B cells expressing CD19. One preferred method is where the anti-CD19 proapoptotic MAb or a Fc optimized proapototic humanized MAb. In the methods of the present invention some anti-CD20 agents such as Rituxan®, or chemodrugs such as vincristine may be used in combitherapy. The methods of the present invention reduce the levels of B CD19 positive, more particularly in all diffuse large B cells lymphoma (DLBCL) subtypes and in Follicular lymphomas (FL).

This invention relates to treatment of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Specifically, the disclosure provides a method of treating a subject having DLBCL or FL, the method comprising administering to the subject a drug combination consisting essentially of a CD19 antibody drug conjugate (CD19-ADC), and rituximab, cyclophosphamide, doxorubicin, and prednisone (RCHP).

The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer, in particular, of B cell lymphoma or B cell leukemia. The invention provides a nucleic acid encoding TCR alpha or beta chain constructs of TCR constructs capable of specifically binding to a peptide of SEQ ID NO: 1, derived from the lineage specific antigen CD22, in the context of HLA-A2 and to subsequently lyse CD22-positive cells. The invention further provides a corresponding protein and host cell, e.g., a CD8+ T cell, pharmaceutical compositions comprising the same, and therapeutic use for treatment of B cell lymphoma or B cell leukemia, such as diffuse large B-cell lymphoma (DLBCL).